Editas Medicine (EDIT) Tops Q4 EPS by 36c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.23), $0.36 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $60.04 million versus the consensus estimate of $3.7 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Exyn Technologies, Inc. (EXYN) Reports Q2 Loss of $1.55
• Lowe's slashes full-year sales outlook amid DIY spending pressure